Patents Represented by Attorney, Agent or Law Firm Kathleen Fowler
-
Patent number: 7648702Abstract: The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.Type: GrantFiled: April 6, 2007Date of Patent: January 19, 2010Assignee: Immunex CorporationInventors: Wayne R. Gombotz, Richard L. Remmele, Jr.
-
Patent number: 7544784Abstract: The invention provides methods of increasing yields of desired conformation of proteins. In particular embodiments, the invention includes contacting preparations of a recombinant protein with a reduction/oxidation coupling reagent for a time sufficient to increase the relative proportion of a desired configurational isomer.Type: GrantFiled: November 22, 2006Date of Patent: June 9, 2009Assignee: Immunex CorporationInventors: Helmut M. Sassenfeld, Richard L. Remmele, Jr., Rebecca E. McCoy
-
Patent number: 7276477Abstract: The present invention relates to crystalline etanercept and to methods of making crystalline etanercept; to pharmaceutical compositions comprising crystalline etanercept; and to therapeutic uses of such compositions.Type: GrantFiled: July 29, 2004Date of Patent: October 2, 2007Assignee: Amgen Inc.Inventors: Timothy D. Osslund, Christi L. Clogston, Shon Lee Crampton, Randal B. Bass
-
Patent number: 7166445Abstract: The invention provides improved methods of recombinant protein production in cell culture. More specifically, the invention relates to the modulation of the IGF-1 signaling pathway in cells so as to improve production characteristics.Type: GrantFiled: February 28, 2005Date of Patent: January 23, 2007Assignee: Immunex CorporationInventors: Arvia E. Morris, Pranhitha Reddy
-
Patent number: 7157557Abstract: The invention provides methods of increasing yields of desired conformation of proteins. In particular embodiments, the invention includes contacting preparations of a recombinant protein with a reduction/oxidation coupling reagent for a time sufficient to increase the relative proportion of a desired configurational isomer.Type: GrantFiled: February 22, 2002Date of Patent: January 2, 2007Assignee: Immunex CorporationInventors: Helmut M. Sassenfeld, Richard L. Remmele, Jr., Rebecca E. McCoy
-
Patent number: 7101982Abstract: The invention provides methods of controlling pH variations during chromatography. In particular embodiments, the invention includes equilibrating and eluting proteins from chromatography resins have a solid phase that possesses a charged functional group on its backbone under controlled conditions of osmolarity and pH. The invention is particularly useful in the purification of proteins that are sensitive to pH transitions such as, for example, the IL-1 Receptor type II protein.Type: GrantFiled: March 29, 2002Date of Patent: September 5, 2006Assignee: Immunex CorporationInventors: Sanchayita Ghose, Thomas M. McNerney
-
Patent number: 7091004Abstract: The invention provides cells that produce increased levels of recombinant protein by modulating the activity of translational regulator gene products that are downstream targets of PKB alpha, methods of making such cells, and methods of using such cells. Such translational regulator gene products include 4E-BP1 and mTOR.Type: GrantFiled: June 7, 2002Date of Patent: August 15, 2006Assignee: Immunex CorporationInventors: Arvia E. Morris, Sharon T. Wong-Madden
-
Patent number: 6972327Abstract: The invention provides improved methods of regenerating and using affinity chromatography material, in particular Protein A affinity chromatography resins.Type: GrantFiled: May 8, 2002Date of Patent: December 6, 2005Assignee: Immunex CorporationInventors: Hassan Madani, Robert D. Hershberg
-
Patent number: 6924124Abstract: The invention is in the field of cell culture, particularly recombinant cell culture. More specifically, the invention relates to methods of fed batch CHO cell culture.Type: GrantFiled: August 23, 2002Date of Patent: August 2, 2005Assignee: Immunex CorporationInventor: Pankaj Singh
-
Patent number: 6897040Abstract: The invention provides improved methods of recombinant protein production in cell culture. More specifically, the invention relates to the modulation of the IGF-1 signaling pathway in cells so as to improve production characteristics.Type: GrantFiled: March 29, 2002Date of Patent: May 24, 2005Assignee: Immunex CorporationInventors: Arvia E. Morris, Pranhitha Reddy
-
Patent number: 6774224Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: August 5, 2002Date of Patent: August 10, 2004Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 6670135Abstract: This invention provides a method comprising assaying the binding of a DCSema polypeptide to a VESPR protein.Type: GrantFiled: October 12, 2000Date of Patent: December 30, 2003Assignee: Immunex CorporationInventor: Melanie K. Spriggs
-
Patent number: 6632637Abstract: There is disclosed an expression vector utilizing an internal polyadenylation signal. The internal polyadenylation signal is inserted between a DNA encoding a protein of interest and a DNA encoding a selectable marker, and allows a single promoter to generate both monocistronic messages and dicistronic messages. Similar, multicistronic vectors can also be prepared. Also disclosed are methods of using the expression vector utilizing an internal polyadenylation signal, host cells transfected therewith, stable pools of cells transfected with an expression vector utilizing an internal polyadenylation signal, and clones of such transfected cells.Type: GrantFiled: October 12, 2000Date of Patent: October 14, 2003Assignee: Immunex CorporationInventor: Jeffrey T. McGrew
-
Patent number: 6596514Abstract: There are disclosed nucleotide sequences which can improve expression of recombinant proteins two- to eight-fold in stable cell pools when present in an expression vector.Type: GrantFiled: October 9, 2001Date of Patent: July 22, 2003Assignee: Immunex CorporationInventors: Arvia E. Morris, James N. Thomas
-
Patent number: 6562949Abstract: The invention is directed to VESPR polypeptides as a purified and isolated protein, the DNA encoding the VESPR polypeptide, host cells transfected with cDNAs encoding VESPR, and methods for preparing VESPR polypeptides.Type: GrantFiled: December 10, 1999Date of Patent: May 13, 2003Assignee: Immunex CorporationInventors: Melanie K. Spriggs, Michael R. Comeau, Robert F. DuBose, Richard S. Johnson
-
Patent number: 6555520Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: May 9, 2001Date of Patent: April 29, 2003Assignee: Immunex CorporationInventors: John E. Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Armstrong
-
Patent number: 6492140Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.Type: GrantFiled: January 3, 2001Date of Patent: December 10, 2002Assignee: Immunex CorporationInventors: Douglas P. Cerretti, Pranhitha Reddy
-
Patent number: 6492496Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation. In addition, antibodies specific to 2F1 polypeptide are provided.Type: GrantFiled: May 24, 2000Date of Patent: December 10, 2002Assignee: Immunex CorporationInventors: Patricia Parnet, John E. Sims
-
Patent number: 6458350Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: March 22, 2000Date of Patent: October 1, 2002Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 6451760Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.Type: GrantFiled: May 24, 2000Date of Patent: September 17, 2002Assignee: Immunex CorporationInventors: Patricia Parnet, John E. Sims